Hope-Simpson, R. The nature of herpes zoster: a long-term study and a new hypothesis. Proceedings of the Royal Society of Medicine
1965; 58: 9–20.
Thomas, S, Hall, A. What does epidemiology tell us about risk factors for herpes zoster?
Lancet Infectious Diseases
2004; 4: 26–33.
Langan, S, et al.
Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Medicine
2013; 10: e1001420.
Buchbinder, S, et al.
Herpes zoster and human immunodeficiency virus infection.
Journal of Infectious Diseases
1992; 166: 1153–1156.
Fleming, D, et al.
Gender differences in the incidence of shingles. Epidemiology and Infection
2003; 132: 1–5.
Schmader, KE, et al.
Race and stress in the incidence of herpes zoster in older adults. Journal of the American Geriatrics Society
1998; 46: 973–977.
Zhang, J, et al.
Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. Journal of the American Medical Association
2012; 308: 43–49.
Thomas, S, Wheeler, J, Hall, A. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet
2002; 360: 678–682.
Irwin, M, et al.
Cellular immunity to varicella-zoster virus in patients with major depression. Journal of Infectious Diseases
1998; 178: S104–108.
Weitzman, D, et al.
A population based study of the epidemiology of Herpes Zoster and its complications. Journal of Infection
2013; 67: 463–469.
Oxman, M, et al.
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine
2005; 352: 2271–2284.
Schmader, K, et al.
Persistence of the efficacy of zoster vaccine in the Shingles Prevention Study and the Short-Term Persistence Substudy. Clinical Infectious Diseases
2012; 55: 1320–1328.
45 and Up Study Collaborators, Banks, E, Redman, S, et al.
Cohort profile: the 45 and up study. International Journal of Epidemiology
2008; 37: 941–947.
National Centre for Classification in Health (Sydney). The international statistical classification of diseases and related health problems, 10th revision, Australian Modification (ICD-10-AM), 2nd edn. Lidcombe, NSW: National Centre for Classification in Health Sydney, 2000.
Dworkins, R, et al.
Recommendations for the management of herpes zoster. Clinical Infectious Diseases
2007; 44: S1–26.
Centers for Disease Control and Prevention. Prevention of herpes zoster. Recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report
2008; 57: RR-5.
Stein, A, et al.
Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine
2009; 27: 520–529.
MacIntyre, C, Chu, C, Burgess, M. Use of hospitalization and pharmaceutical prescribing data to compare the prevaccination burden of varicella and herpes zoster in Australia. Epidemiology and Infection
2003; 131: 675–682.
Yawn, B, Wollan, P, Sauver, J. Comparing shingles incidence and complication rates from medical record review and administrative database estimates: how close are they?
American Journal of Epidemiology
2011; 174: 1054–1061.
Jackson, LA, Reynolds, M, Harpaz, R. Hospitalizations to treat herpes zoster in older adults: causes and validated rates. Clinical Infectious Diseases
2008; 47: 754–9.
Ultsch, B, et al.
Herpes zoster in Germany: quantifying the burden of disease. BMC Infectious Diseases
2011; 11: 173.
Australian Institute of Health and Welfare. Rural, regional and remote health: a guide to remoteness classifications. Canberra: AIHW Catalogue, PHE 53, 2004.
Hays, R, et al.
Item response theory analyses of physical functioning items in the Medical Outcomes Study. Medical Care
2007; 45: S32–S8.
Opstelten, W, et al.
Gender as an independent risk factor for herpes zoster: a population-based prospective study. Annals of Epidemiology
2006; 16: 692–695.
Tseng, HF, et al.
Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. Journal of the American Medical Association
2011; 305: 160–166.
Habel, L, et al.
The epidemiology of herpes zoster in patient with newly diagnosed cancer. Cancer Epidemiology Biomarkers and Prevention
2013; 22: 82–90.
Forbes, H, et al.
Quantification of risk factors for herpes zoster: population based case-control study. British Medical Journal
2014; 348: g2911.
Chiappe, S, et al.
Herpes zoster: burden of disease in France. Vaccine
2010; 28: 7933–7938.
Insinga, R, et al.
The incidence of herpes zoster in a United States administrative database. Journal of General Internal Medicine
2005; 20: 748–753.
Ogunjimi, B, Van Damme, P, Beutels, P. Herpes zoster risk reduction through exposure to chickenpox patients: a systematic multidisciplinary review. PLoS ONE
2013; 8: e66485.
Castle, S. Clinical relevance of age-related immune dysfunction. Clinical Infectious Diseases
2000; 31: 578–585.
Morrison, V, et al.
Safety of zoster vaccine in elderly adults following documented herpes zoster. Journal of Infectious Diseases
2013; 208: 559–563.